TY - JOUR
T1 - Insulin Treatment Attenuates Decline of Muscle Mass in Japanese Patients with Type 2 Diabetes
AU - Bouchi, Ryotaro
AU - Fukuda, Tatsuya
AU - Takeuchi, Takato
AU - Nakano, Yujiro
AU - Murakami, Masanori
AU - Minami, Isao
AU - Izumiyama, Hajime
AU - Hashimoto, Koshi
AU - Yoshimoto, Takanobu
AU - Ogawa, Yoshihiro
N1 - Funding Information:
This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
Publisher Copyright:
© 2017, The Author(s).
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Sarcopenia is defined as an age-related loss of skeletal muscle mass and strength, and is a major cause of disability and mobility limitations. Recent studies have demonstrated that type 2 diabetes and insulin signaling deficiencies contribute to the progression of sarcopenia, suggesting that a sufficient supply of insulin to the skeletal muscles may be important for the maintenance of muscle function; however, little has been reported regarding whether insulin treatment can protect against sarcopenia. We conducted a retrospective observational study to examine the impact of insulin treatment on the muscle mass of patients with type 2 diabetes. A total of 312 patients (mean age: 64 ± 11 years; 40.8% female; 27.6% treated with insulin) were studied in this retrospective observational study. Skeletal muscle index (SMI) and grip strength (kg) were used to assess sarcopenia. The prevalence of sarcopenia was 18.0%. Insulin treatment was shown to be protective against the annual decline of SMI (standardized β 0.195; p = 0.025) even after adjusting for covariates, including age, gender, duration of diabetes, and body mass index. In a cohort matched by propensity scores, insulin treatment significantly increased the 1-year change in SMI (mean ± SE) compared with non-insulin-treated group (2.40 ± 0.98% vs. −0.43 ± 0.98%; p = 0.050). Our data suggest that insulin treatment could attenuate the progression of sarcopenia in patients with type 2 diabetes.
AB - Sarcopenia is defined as an age-related loss of skeletal muscle mass and strength, and is a major cause of disability and mobility limitations. Recent studies have demonstrated that type 2 diabetes and insulin signaling deficiencies contribute to the progression of sarcopenia, suggesting that a sufficient supply of insulin to the skeletal muscles may be important for the maintenance of muscle function; however, little has been reported regarding whether insulin treatment can protect against sarcopenia. We conducted a retrospective observational study to examine the impact of insulin treatment on the muscle mass of patients with type 2 diabetes. A total of 312 patients (mean age: 64 ± 11 years; 40.8% female; 27.6% treated with insulin) were studied in this retrospective observational study. Skeletal muscle index (SMI) and grip strength (kg) were used to assess sarcopenia. The prevalence of sarcopenia was 18.0%. Insulin treatment was shown to be protective against the annual decline of SMI (standardized β 0.195; p = 0.025) even after adjusting for covariates, including age, gender, duration of diabetes, and body mass index. In a cohort matched by propensity scores, insulin treatment significantly increased the 1-year change in SMI (mean ± SE) compared with non-insulin-treated group (2.40 ± 0.98% vs. −0.43 ± 0.98%; p = 0.050). Our data suggest that insulin treatment could attenuate the progression of sarcopenia in patients with type 2 diabetes.
UR - http://www.scopus.com/inward/record.url?scp=85014000615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014000615&partnerID=8YFLogxK
U2 - 10.1007/s00223-017-0251-x
DO - 10.1007/s00223-017-0251-x
M3 - Article
C2 - 28246927
AN - SCOPUS:85014000615
SN - 0171-967X
VL - 101
SP - 1
EP - 8
JO - Calcified Tissue International
JF - Calcified Tissue International
IS - 1
ER -
